Therapeutic trial & Research projects

 

THERAPEUTIC TRIALS

  • Title: Randomized open label study to compare the efficacy and safety   of everolimus followed by chemotherapy with STZ-5FU upon progression or  the reverse sequence, chemotherapy with STZ-5FU  followed by  everolimus  upon progression, in advanced progressive pNETs  (SEQTOR)

          Status: ongoing

 

  • Title: Trial to assess the efficacy of lenvatinib in metastatic  neuroendocrine tumors (TALENT)

          Status: ongoing

 

  • Title: Efficacy and safety of lanreotide autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide autogel® 120 mg administered every 28 days (CLARINET FORTE)

          Status: ongoing –

 

  • Title:  Efficacy and safety of lanreotide autogel 120 mg in combination with temozolomide in subjects with progressive well differentiated thoracic neuroendocrine tumors. A pilot phase II study (ATLANT)

          Status: ongoing -

 

 

  • Title: First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paraganglioma (FIRSTMAPP)

          Status: ongoing –

 

  • Title: Efficacy of lanreotide in patients with Multiple Endocrine Neoplasia type 1 (MEN1) with progressive duodenum-pancreatic neuroendocrine (LAN in MEN1 vs FOLLOW UP)

          Status: ongoing 

 

  • Title: Phase II trial to evaluate the efficacy and safety of Temozolomide in second-line in patients with Neuroendocrine Tumor of pancreatic , gastrointestinal or pulmonary origing progressing after prior first line chemotherapy platinum-based (TENEC)

          Status: ongoing 

 

  • Title: A Phase II Single Arm Trial Evaluating the Clinical impact of Octreotide LAR in the induction of immunologic response in patient with  Neuroendocrine Tumors ( IMMUNeOCT)

          Status: under evaluation

 

  • Title: An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin who have progressed on prior treatment . (Oncology Clinical Protocol CPDR001E2201)

          Status: under evaluation

 

  •  Title: Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymus – (LUNA)

          Status: closed 

 

  • Title: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin – (RADIANT-4)

         Status: closed

 

  • Title: Open label extension study of Lanreotide Autogel 120 mg in patients with non functioning entero pancreatic endocrine tumour (CLARINET - OLE)

          Status: closed

 

  • Title: Sicurezza del trattamento con lanreotide ad alte dosi in pazienti affetti da tumori neuroendocrini scarsamente responsivi al trattamento con analoghi della somatostatina a dosi standard (LAN HD)

          Status: closed

 

  •  Title: Mono centre, open label proof of concept study SOM230 in progressive medullary thyroid cancer patients and the combination with RAD001 upon progression (SOM RAD)

          Status: closed  

 

 

RESEARCH PROJECTS:

 

  • Title: Cytokines as predictive factors of response to SSA treatment in neuroendocrine tumour patients (SSA CYTOKINES)

          Status: ongoing   

   

  • Title: Therapeutic sequence in patients with neuroendocrine tumors (NET): an observational, multicentre, retrospective study (ELIOS STUDY)

          Status: ongoing

 

  • Title: Antigenic targets for immunotherapy of MEN1-associated pancreatic neuroendocrine tumors (pNETs)

         Status: ongoing